Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China

Chen, Wanlu; Ding, Heng; Cheng, Yujing; Li, Qi; Dai, Run; Yang, Xin; Zhang, Chan

doi:10.1002/mgg3.884

Cited by 10 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And we downloaded 26 population data from the 1000 genomes project (http://www.internationalgenome.org/). 2,3,18,19 P < .05/(50*27) indicated that the locus has statistically significant.…”

Section: Resultsmentioning

confidence: 99%

“…In the study, we selected 50 VIP variants located in 27 genes from the PharmGKB database (http://www.pharmgkb.org). 18,19 Genomic DNA was extracted from 5mL peripheral blood sample according to the guidelines of GoldMag‐Mini Whole Blood Genomic DNA Purification Kit (GoldMag Ltd.). The concentration and purity of genomic DNA was detected by NanoDrop 2000C spectrophotometer (Thermo Scientific).…”

Section: Methodsmentioning

confidence: 99%

“…We downloaded the data of 26 populations from the 1000 genomes project (http://www.internationalgenome.org/). 18,19 The 26 populations are as follows: (1) ACB, African Caribbean in Barbados; (2) ASW, African Ancestry in Southwest US; (3) BEB, Bengali in Bangladesh; (4) CDX, Chinese Dai in Xishuangbanna, China; (5) CEU, Utah residents with Northern and Western European ancestry; (6) CHB, Han Chinese in Beijing, China; (7) CHS, Southern Han Chinese, China; (8) CLM, Colombian in Medellin, Colombia; (9) ESN, Esan in Nigeria; (10) FIN, Finnish in Finland; (11) GBR, British in England and Scotland; (12) GIH, Gujarati Indian in Houston, TX; (13) GWD, Gambian in Western Division, The Gambia; (14) IBS, Iberian populations in Spain; (15) ITU, Indian Telugu in the UK; (16) JPT, Japanese in Tokyo, Japan; (17) KHV, Kinh in Ho Chi Minh City, Vietnam; (18) LWK, Luhya in Webuye, Kenya; (19) MSL, Mende in Sierra Leone; (20) MXL, Mexican Ancestry in Los Angeles, California; (21) PEL, Peruvian in Lima, Peru; (22) PJL, Punjabi in Lahore, Pakistan; (23) PUR, Puerto Rican in Puerto Rico; (24) STU, Sri Lankan Tamil in the UK; (25) TSI, Toscani in Italy; and (26) YRI, Yoruba in Ibadan, Nigeria.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Analysis of very important pharmacogene variants in the Tibetan population from China

Rong

Dong

et al. 2021

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Personalized medicine, the treatment best suited for an individual, is a hot field of clinical research in the world. Many recent studies have shown that genetic variations have a great influence on the treatment. This study aimed to identify the distribution differences of very important pharmacogene (VIP) variants between the Tibetan population and the other 26 populations from the 1000 Genomes project. Based on the PharmGKB database, we successfully genotyped 50 VIP variants located in 27 genes in the Tibetan population. We also compared the genotype frequencies of VIP variants between Tibetan population and the other 26 populations. Without adjustment, the Chi‐square test showed that the only significant variant between Tibetans and every other group was rs1801159 in dihydropyrimidine dehydrogenase (DPYD), followed by rs1800566 in NAD(P)H quinone dehydrogenase 1 (NQO1) and rs1051296 in solute carrier family 19 member 1 (SLC19A1). After Bonferroni's multiple adjustments, the genotype frequencies distribution of DPYD rs1801159 was found to be different in Tibetans compared to the other 26 groups, apart from ACB and ASW. Moreover, genetic structure/F‐statistics (Fst) analysis and the phylogenetic tree illustrated that Tibetans had a closer affinity with CDX, CHB, CHS, JPT and KHV. Our data will complement pharmacogenomics information of the Tibetan population and provide theoretical support for the realization of individualized medical treatment for Tibetans in the future.

show abstract

“…And we downloaded 26 population data from the 1000 genomes project (http://www.internationalgenome.org/). 2,3,18,19 P < .05/(50*27) indicated that the locus has statistically significant.…”

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of very important pharmacogene variants in the Tibetan population from China

Rong

Dong

et al. 2021

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…The SLC19A1 gene encodes a folate transporter and is involved in the regulation of intracellular folate concentration [ 29 ]. Studies have shown that folate carrier protein 1 ( SLC19A1 ) affects the transport process of pemetrexed in the body.…”

Section: Discussionmentioning

confidence: 99%

Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China

Peng

Xing

et al. 2021

BMC Genom Data

View full text Add to dashboard Cite

Background The variation of drug responses and target does among individuals is mostly determined by genes. With the development of pharmacogenetics and pharmacogenomics, the differences in drug response between different races seem to be mainly caused by the genetic diversity of pharmacodynamics and pharmacokinetics genes. Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB). The information of Chinese ethnic minorities such as the Wa ethnic group is scarce. This study aimed to uncover the significantly different loci in the Wa population in Yunnan Province of China from the perspective of pharmacogenomics, to provide a theoretical basis for the future medication guidance, and to ultimately achieve the best treatment in the future. Results In this study, we recruited 200 unrelated healthy Wa adults from the Yunnan province of China, selected 52 VIP variants from the PharmGKB for genotyping. We also compared the genotype frequency and allele distribution of VIP variants between Wa population and the other 26 populations from the 1000 Genomes Project (http://www.1000Genomes.org/). Next, χ2 test was used to determine the significant points between these populations. The study results showed that compared with the other 26 population groups, five variants rs776746 (CYP3A5), rs4291 (ACE), rs3093105 (CYP4F2), rs1051298 (SLC19A1), and rs1065852 (CYP2D6) had higher frequencies in the Wa population. The genotype frequencies rs4291-TA, rs3093105-CA, rs1051298-AG and rs1065852-GA were higher than those of the other populations, and the allele distributions of rs4291-T and rs3093105-C were significantly different. Additionally, the difference between the Wa ethnic group and East Asian populations, such as CDX, CHB, and CHS, was the smallest. Conclusions Our research results show that there is a significant difference in the distribution of VIP variants between the Wa ethnic group and the other 26 populations. The study results will have an effect on supplementing the pharmacogenomics information for the Wa population and providing a theoretical basis for individualised medication for the Wa population.

show abstract

“…Then we used dbSNP database to conduct frequency search for the screened variants, and retained the variants with altered alleles greater than 0.05 in the Han population of Beijing, China (CHB), in order to increase the statistical efficacy. 24 Finally, PGx biomarkers that have been reported and recommended for drug dose adjustment by global drug regulatory agencies are selected as candidate SNPs from these SNPs according to published literature. 25 Based on the above criteria and methods, we used SNPscan TM technology to genotype candidate SNPs, and excluded those SNPs that could not be successfully genotyped.…”

Section: Variant Selection and Genotypingmentioning

confidence: 99%

Genetic Polymorphism of Drug Metabolic Gene CYPs, VKORC1, NAT2, DPYD and CHST3 of Five Ethnic Minorities in Heilongjiang Province, Northeast China

Zhang¹,

Li²,

Dong³

et al. 2021

PGPM

View full text Add to dashboard Cite

Introduction: Genetic variability in genes encoding drug-metabolizing enzymes may contribute to the heterogeneity of drug responses in different populations. Extensive research in pharmacogenomics in major populations around the world provides us with a great deal of information about drug-related genetic polymorphisms. Objective: The purpose of this study was to detect the genetic variation of drug-metabolism -related genes in the five ethnic minorities Daur, Hezhen, Ewenki, Mongolian and Manchu in China, and to analyze the distribution differences among ethnic groups. Methods: We genotyped 32 SNPs of drug metabolism genes in 882 healthy Chinese volunteers from five ethnic groups. The genotype frequency and allele frequency of the five ethnic groups were calculated, and the different variants among the five ethnic groups were compared by chi-square test. Genetic parameters were analyzed using Popgene software. The genetic structure of five ethnic minorities was analyzed by principal component analysis, and compared with 26 populations. Results: We found that SNPs of genes related to drug metabolism existed diversity in different populations. Among them, rs8192766 and rs9419082 in CYP2E1 showed statistical differences between Daur and Manchu, and NAT2 rs1801280 showed statistical differences between Hezhen and Mongolian. In addition, the five populations we studied had the smallest differences with EAS populations. There was haplotype diversity in CHST3, VKORC1, CYP1A2 and CYP2E1 genes in the five ethnic minorities, and these haplotype polymorphisms were related to the use of corresponding drug doses. Cluster analysis shows that the five ethnic minorities in Heilongjiang Province are clustered together with the EAS populations. Conclusion: These results suggest that understanding the diversity of drug-related genetic markers is critical for individualized drug gene therapy programs in ethnic minorities in China as well as in populations highly mixed with these ethnic groups.

show abstract

Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China

Cited by 10 publications

References 28 publications

Analysis of very important pharmacogene variants in the Tibetan population from China

Analysis of very important pharmacogene variants in the Tibetan population from China

Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China

Genetic Polymorphism of Drug Metabolic Gene CYPs, VKORC1, NAT2, DPYD and CHST3 of Five Ethnic Minorities in Heilongjiang Province, Northeast China

Contact Info

Product

Resources

About